2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5896 Host immunogenetics as a new frontier in CAR T toxicity: Synergistic interaction between HLA-DRB1*15 and tocilizumab is associated with ICANS following CAR T-cell therapy

Aleksandr Lazaryan, MD MPH PhD, Ghada Araji, MD2, Mandy O'Leary, MD, MPH3, Jongphil Kim, PhD4, ANM Nazmul Hasan Khan, MBBS, PhD5, Matthew J. Cortese, MD, MPH6, Nima Ghalehsari, MD7, Alaa Ali, MD8, Sayeef Mirza, BS, MPH, MD9, Bijal Shah, MD, MS10, Sameh Gaballa, MD11, Supreet Kaur, MD12, Taiga Nishihori, MD13, Rawan Faramand, MD14, Farhad Khimani, MD15, Nelli Bejanyan, MD16, Michael D. Jain, MD, PhD17, Fabiana Perna, MD, PhD18, Frederick L. Locke, MD19, Michael Ombrello, MD20, Brahm Segal, MD21
1 Moffitt Cancer Center, Tampa, United States
2 Moffitt Cancer Center, Tampa, United States
3 Moffitt Cancer Center, Tampa, United States
4 Moffitt Cancer Center, Tampa, United States
5 Moffitt Cancer Center, Tampa, United States
6 Roswell Park Cancer Center, Buffalo, New York, United States
7 Moffitt Cancer Center, Tampa, United States
8 Moffitt Cancer Center, Tampa, United States
9 Moffitt Cancer Center, Tampa, United States
10 Moffitt Cancer Center, Tampa, United States
11 Moffitt Cancer Center, Tampa, United States
12 Moffitt Cancer Center, Tampa, United States
13 Moffitt Cancer Center, Tampa, United States
14 Moffitt Cancer Center, Tampa, United States
15 Moffitt Cancer Center, Tampa, United States
16 Moffitt Cancer Center, Tampa, United States
17 Moffitt Cancer Center, Tampa, United States
18 Moffitt Cancer Center, Tampa, United States
19 Moffitt Cancer Center, Tampa, United States
20 National Institute of Arthritis & Musculoskeletal & Skin Diseases, Bethesda, Maryland, United States
21 Moffitt Cancer Center, Tampa, United States

Background: Immune effector cell-associated neurotoxicity syndrome (ICANS) remains a major complication of CAR T-cell therapy and is driven by systemic inflammation, endothelial injury, and blood-brain barrier dysfunction. Host genetic susceptibility to ICANS remains poorly understood. Emerging evidence implicates complement activation in ICANS pathogenesis. We recently demonstrated evidence of complement activation during severe ICANS after axicabtagene ciloleucel (axi-cel) for large B-cell lymphoma, including decreased C3 and increased C3a levels with normal C4, a pattern suggestive of alternative pathway activation (Lazaryan et al., EBMT–EHA CAR T, 2026). Alternative pathway activation can be triggered by cellular injury and may amplify endothelial damage. HLA-DRB1*15 is strongly associated with hyperinflammatory drug-associated immune reactions and resides within the ancestral 7.1 haplotype containing several complement pathway genes. Tocilizumab (toci), a cornerstone therapy for CRS, contains polysorbate 80, an excipient capable of complement activation. We therefore investigated whether HLA-DRB1*15 influences ICANS susceptibility and interacts with toci exposure in patients receiving CAR T-cell therapy.
Methods: We conducted a retrospective cohort study of CAR T recipients treated at Moffitt Cancer Center from 2015 through 2025. Among these patients, 140 with available high-resolution HLA typing obtained during routine alloHCT evaluation comprised the analytic cohort. Patients received axi-cel or brexucabtagene autoleucel (brexu-cel) for B-cell non-Hodgkin lymphoma (B-NHL) or B-cell acute lymphoblastic leukemia (B-ALL). The primary endpoint was grade ≥2 ICANS; grade ≥3 ICANS was analyzed as a secondary endpoint. Univariable and multivariable logistic regression models evaluated associations with ICANS. Interaction between DRB1*15 and toci was assessed on additive and multiplicative scales using odds ratios (OR), relative excess risk due to interaction (RERI), attributable proportion (AP), and synergy index (S).
Results: Among 143 CAR T infusions, 94 (65.7%) were for B-NHL and 49 (34.3%) for B-ALL. Median age was 57 years (range, 18–81), and 93 patients (65.0%) were male. HLA-DRB1*15 was present in 30 of 140 patients (21.4%), corresponding to 32 DRB1*15+ infusions (22.4%). Grade ≥2 ICANS occurred in 49 (34.3%) infusions and grade ≥3 ICANS in 33 (23.1%). DRB1*15 carriage alone was not associated with CRS, ICANS, or baseline CRP or ferritin (all p≥0.6). However, a previously unrecognized gene-treatment interaction emerged between DRB1*15 and toci exposure. Grade ≥2 ICANS incidence was 14.6%, 47.6%, 5.6%, and 78.6% among DRB1*15-/toci-, DRB1*15-/toci+, DRB1*15+/toci-, and DRB1*15+/toci+ infusions, respectively (p<0.0001), supporting effect modification by toci exposure. Additive interaction analyses demonstrated substantial biologic synergy, with 75% of grade ≥2 ICANS risk and 81% of grade ≥3 ICANS risk in the jointly exposed group attributable to interaction (AP 0.75 and 0.81; S 4.9 and 7.4, respectively). Multiplicative interaction modeling of grade ≥2 ICANS using Firth penalized logistic regression demonstrated a large interaction effect (OR 7.66, 95% CI 0.97–104; likelihood-ratio [LR] p=0.05), while DRB1*15 alone was not associated with grade ≥2 ICANS (OR 0.47, 95% CI 0.05–2.42; LR p=0.29). Toci exposure was associated with increased grade ≥2 ICANS risk in a dose-stratified model (1 dose: OR 4.17, 95% CI 1.57–12.00; ≥2 doses: OR 6.37, 95% CI 2.31–19.13; both LR p<0.01). Similar findings were observed for severe ICANS, with an interaction-attributable excess risk of 40.5%. Exploratory analyses suggested that the interaction signal was enriched in B-NHL, consistent with disease-specific tumor microenvironment-driven amplification of host immunogenetic susceptibility.
Conclusions: Although CAR T antitumor activity is HLA-independent, susceptibility to neurotoxicity may not be. HLA-DRB1*15 demonstrated substantial interaction with toci exposure on both additive and multiplicative scales. DRB1*15 carriers exposed to toci experienced exceptionally high rates of neurotoxicity, with 78.6% developing grade ≥2 ICANS and 64.3% developing grade ≥3 ICANS. Together with emerging evidence implicating complement activation in ICANS, these findings support a novel HLA-complement-cytokine amplification model of CAR T neurotoxicity and establish host immunogenetics as a new frontier for toxicity prediction and mitigation.

Aleksandr Lazaryan, MD MPH PhD: Pierre Fabre - Honoraria; Incyte and Subsidiaries - Honoraria; Sanofi - Honoraria; Incyte and Subsidiaries - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Pierre Fabre - Consultancy (Includes expert testimony)